New Analysis from Phase 2b Study Reinforces Favorable Survival Data Observed with FOLOTYN® Relative to Erlotinib in …
New Analysis from Phase 2b Study Reinforces Favorable Survival Data Observed with FOLOTYN® Relative to Erlotinib in …
Allos Therapeutics, Inc. today announced the presentation of further data from the Company’s randomized, international Phase 2b investigational study of FOLOTYN® relative to erlotinib in patients with Stage IIIB/IV non-small cell lung cancer at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology.
Read more on Business Wire via Yahoo! Finance
Categories: Breast Cancer Information Tags: Analysis, Data, Erlotinib, Favorable, FOLOTYN®, From, Observed, Phase, Reinforces, relative, Study, Survival
Debi’s story: Breast Cancer Survival
After discovering a lump in her breast during a self exam, Debi, 52, was diagnosed with Stage 2 Grade 3 breast cancer. With her “trio of doctors,” she received chemotherapy, a lumpectomy and radiation through St. Francis Hospital & Health Centers.
In Spite Of Better Survival Odds, Cancer Experience Worse For Young Adults
In Spite Of Better Survival Odds, Cancer Experience Worse For Young Adults
Younger adult cancer patients have the most difficulty coping with the pain and emotional issues of cancer, in spite of their potentially better survival odds, according to a University of Michigan Health System study. The study, which included mostly breast and lung cancer patients, appears in the November issue of Pain Medicine, a journal of the American Academy of Pain Medicine. Adult cancer …
Read more on Medical News Today
Categories: Breast Cancer Information Tags: Adults, Better, cancer, experience, Odds, Spite, Survival, Worse, Young
Afatinib (BIBW 2992*) Triples Progression Free Survival in Phase III Study in Lung Cancer Patients
Afatinib (BIBW 2992*) Triples Progression Free Survival in Phase III Study in Lung Cancer Patients
MILAN, Italy & INGELHEIM, Germany–(BUSINESS WIRE)–FOR NON-US MEDIA ONLY Boehringer Ingelheim announced today promising results from two clinical trials of its investigational cancer compound afatinib (BIBW 2992) presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy. Results from the “LUX-Lung 1” trial suggest that afatinib (BIBW 2992) is highly active in …
Read more on Business Wire
Categories: Breast Cancer Information Tags: 2992*, Afatinib, BIBW, cancer, free, lung, Patients, Phase, Progression, Study, Survival, Triples
In Phase II Trial, Vaccine Extends Glioblastoma Patients’ Survival
In Phase II Trial, Vaccine Extends Glioblastoma Patients’ Survival
A vaccine that turns the immune system against brain tumor cells bearing a genetic mutation that drives the most aggressive form of glioblastoma multiforme improved survival of patients in a phase II clinical trial, researchers at Duke University and The University of Texas MD Anderson Cancer Center reported today in the Journal of Clinical Oncology…
Read more on Medical News Today
Categories: Breast Cancer Tumor Tags: Extends, glioblastoma, Patients, Phase, Survival, Trial, vaccine